Rowan Walrath

Rowan Walrath

@rowanwalrath.bsky.social

Associate editor, life sciences reporter @cenmag.bsky.social. Texan Bostonian. she/her. r_walrath@acs.org. For sensitive tips, I'm on Signal @rowanwalrath.01 or email rowan.walrath@proton.me

871 followers1K following190 posts

Fun to chat with @craigofwaffles.bsky.social and Shea about what went into Cities of Chemistry! @cenmag.bsky.social

Craig Bettenhausen@craigofwaffles.bsky.social

C&EN's latest podcast episode just dropped, and if you like geography and data, you should check it out! And explore the underlying feature, Cities of Chemistry cen.acs.org/business/Unc... @cenmag.bsky.social @rowanwalrath.bsky.social #data #science #economics #podcast

Heads up: I'll be away the weeks of 9/21 and 9/28. I trust that my sharp C&EN colleagues will capably handle anything that comes up in my absence. I return 10/5, so if you need something from me specifically, I'd reach out or re-up then!

Rowan Walrath reposted

Very very cool interactive data story from some of C&EN's finest!

Rowan Walrath@rowanwalrath.bsky.social

What are the most important ingredients for chemical innovation? For @cenmag.bsky.social, my colleague Shea Murphy and I sought to find out. 🧵

Rowan Walrath reposted

Replying to @rowanwalrath.bsky.social

The coolest part, IMO, is this "build your own city ranking" tool. You can use sliders to adjust how much weight you'd give to one dimension, like VC funding or lab space, and see what cities come out on top.

View full thread
View full thread

These tools are interactive, allowing you to play with data yourself to see what regions are dominant as research centers, chemical industry hubs, and start-up havens—ultimately, whatever matters most to you.

The coolest part, IMO, is this "build your own city ranking" tool. You can use sliders to adjust how much weight you'd give to one dimension, like VC funding or lab space, and see what cities come out on top.

View full thread

Boston & Massachusetts may not house the headquarters of top US pharmaceutical companies, but they commands the most chemistry-related VC investment and the third-highest chemistry article output, reflecting their status as a life sciences hub spanning start-ups, academia, and research hospitals.

View full thread

And you need institutions. Depending on how you’d like your career to unfold, those institutions can include academic centers, big industrial companies, start-up accelerators and incubators, and venture capital firms.

Rowan Walrath reposted

Rowan Walrath reposted

""We’re interested in FcRn inhibitors as a treatment option for a subset of folks with Long COVID...” Putrino [said]." A great story on Vyvgart and Ampligen, and the challenges of study design for Long COVID, POTS, and ME by @rowanwalrath.bsky.social cen.acs.org/pharmaceutic...

cen.acs.orgAccess to potential long COVID drugs dwindles as trials falterTwo sets of studies for COVID-driven conditions show the struggles of drug development

Rowan Walrath reposted

#chemsky thread on long COVID therapies

Rowan Walrath@rowanwalrath.bsky.social

In the picture on her GoFundMe page, Mia Delli Gatti looks bright and cheerful. She sticks out her tongue and curls her left hand into a “rock on” symbol. The sun shines through the short, dark curls that halo her face. 1/

Rowan Walrath reposted

A complicated disease, competing corporate and scientific priorities, and regulatory catch-22s. Please read the results of @rowanwalrath.bsky.social 's reporting as she's tried to better understand the state of drug development for long COVID and related conditions

Rowan Walrath@rowanwalrath.bsky.social

I can't possibly do the story justice in a Twitter thread, so please read it on @cenmag.bsky.social: cen.acs.org/pharmaceutic... 13/13

In the picture on her GoFundMe page, Mia Delli Gatti looks bright and cheerful. She sticks out her tongue and curls her left hand into a “rock on” symbol. The sun shines through the short, dark curls that halo her face. 1/

View full thread

In the picture on her GoFundMe page, Mia Delli Gatti looks bright and cheerful. She sticks out her tongue and curls her left hand into a “rock on” symbol. The sun shines through the short, dark curls that halo her face. 1/

View full thread

Two sets of studies for COVID-driven conditions--one for Vyvgart in long COVID POTS, another for Ampligen in long COVID and ME/CFS--show the struggles of drug development in postinfectious diseases. 12/

In the picture on her GoFundMe page, Mia Delli Gatti looks bright and cheerful. She sticks out her tongue and curls her left hand into a “rock on” symbol. The sun shines through the short, dark curls that halo her face. 1/

View full thread

Some patients have advocated for expanded-access studies that allow them to keep taking experimental medications. But such studies can imperil a drug’s long-term approval prospects. 10/

In the picture on her GoFundMe page, Mia Delli Gatti looks bright and cheerful. She sticks out her tongue and curls her left hand into a “rock on” symbol. The sun shines through the short, dark curls that halo her face. 1/

View full thread

The GoFundMe, which Delli Gatti set up in November, is part of a last-ditch effort to move development of efgartigimod forward after Delli Gatti and other trial participants were left by the wayside. But nothing is a sure bet in long COVID research. 8/

Over the last six months, I've spoken with patients, patient advocates, physicians, researchers, and drug manufacturers to better understand the state of drug development for long COVID and related conditions. 9/

In the picture on her GoFundMe page, Mia Delli Gatti looks bright and cheerful. She sticks out her tongue and curls her left hand into a “rock on” symbol. The sun shines through the short, dark curls that halo her face. 1/

View full thread

Long COVID affects more than 400 million people globally, and it’s a complicated, heterogeneous disease that often overlaps with other illnesses, including POTS and myalgic encephalomyelitis. 6/

In the picture on her GoFundMe page, Mia Delli Gatti looks bright and cheerful. She sticks out her tongue and curls her left hand into a “rock on” symbol. The sun shines through the short, dark curls that halo her face. 1/

View full thread

The trial would ultimately throw Delli Gatti into the unstable world of long COVID research and development, showing how a tangle of competing corporate and scientific priorities—and regulatory catch-22s—have hamstrung experimental treatments for postinfectious conditions. 5/

In the picture on her GoFundMe page, Mia Delli Gatti looks bright and cheerful. She sticks out her tongue and curls her left hand into a “rock on” symbol. The sun shines through the short, dark curls that halo her face. 1/

In real life, Delli Gatti isn’t always able to muster this kind of energy. Don’t get her wrong—she recently graduated college, and she works part time and makes cupcakes during some of her off hours—but she also lives with postural orthostatic tachycardia syndrome. 2/

Rowan Walrath reposted

Scientific American is being sold to LabX Media, publisher of Discover: group.springernature.com/gp/group/med... They've fired me and other union staff, ahead of June 26 vote ratification. My rates are suddenly more reasonable, if you need editing or reporting - Argonaut2026@gmail.com

group.springernature.comSpringer Nature to divest its consumer media businesses | Springer Nature Group | Springer NatureStrategic divestment of consumer media portfolio enables Springer Nature to focus on its core business Transaction supports the long-term development

Rowan Walrath reposted

For all the agency chaos, some bits of the FDA are just getting on with things. Speaking to @rowanwalrath.bsky.social at this year's BIO conference, Vaxart's CEO says they've worked consistently with the same set of reviewers at the agency @cenmag.bsky.social cen.acs.org/pharmaceutic...

cen.acs.org‘We’re prepared for whatever the FDA wants’: A vaccine developer gets back on trackVaxart is weeks away from a key readout from its COVID-19 vaccine-pill trial

Rowan Walrath reposted

This is my favorite climate change chart. Japanese monks, aristocrats, and emperors kept meticulous records of cherry blossom festivals for 1,200 years and accidentally built the world's longest climate dataset.